Protease‐activated receptor‐1 drives pancreatic cancer progression and chemoresistance
暂无分享,去创建一个
D. Richel | C. Spek | K. Queiroz | J. Duitman | C. Noesel | J. Wilmink | K. Shi | Hella L. Aberson
[1] D. Richel,et al. Protease‐activated receptor‐2 induces migration of pancreatic cancer cells in an extracellular ATP‐dependent manner , 2013, Journal of thrombosis and haemostasis : JTH.
[2] Hengyi Xiao,et al. Anti‐tumour strategies aiming to target tumour‐associated macrophages , 2013, Immunology.
[3] V. Heinemann,et al. Systemic treatment of advanced pancreatic cancer. , 2012, Cancer treatment reviews.
[4] Derek S. Chan,et al. The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.
[5] P. Insel,et al. Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease‐activated receptor 1, in cardiac fibroblasts , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] M. Peppelenbosch,et al. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[7] D. H. Cox,et al. Suppression of Arterial Thrombosis Without Affecting Hemostatic Parameters With a Cell-Penetrating PAR1 Pepducin , 2012, Circulation.
[8] N. Akar,et al. The Association of Protease Activated Receptor 1 gene −506 I/D Polymorphism with Disease-Free Survival in Breast Cancer Patients , 2012, Annals of Surgical Oncology.
[9] D. Tuveson,et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.
[10] L. Coussens,et al. Differential macrophage programming in the tumor microenvironment. , 2012, Trends in immunology.
[11] Gerald C. Chu,et al. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma , 2011, Proceedings of the National Academy of Sciences.
[12] Xi-lin Du,et al. Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. , 2011, Japanese journal of clinical oncology.
[13] John Yang,et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. , 2011, The American journal of pathology.
[14] F. Finkelman,et al. Local Macrophage Proliferation, Rather than Recruitment from the Blood, Is a Signature of TH2 Inflammation , 2011, Science.
[15] S. Natsugoe,et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. , 2011, The Journal of surgical research.
[16] Zhao-You Tang,et al. Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.
[17] W. Scheithauer,et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Maitra,et al. The hedgehog pathway and pancreatic cancer. , 2009, The New England journal of medicine.
[19] A. Agarwal,et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. , 2009, Cancer research.
[20] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[21] R. Johns,et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.
[22] A. Sood,et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.
[23] T. Goi,et al. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. , 2008, Anticancer research.
[24] R. Chambers. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? , 2008, British journal of pharmacology.
[25] M. Hollenberg,et al. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more , 2008, British journal of pharmacology.
[26] Douglas B. Evans,et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.
[27] Eithne Costello,et al. Biology and management of pancreatic cancer , 2007, Postgraduate Medical Journal.
[28] Ralph H. Hruban,et al. Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer , 2007, Clinical Cancer Research.
[29] R. Vessella,et al. Overexpression of protease‐activated receptors‐1,‐2, and‐4 (PAR‐1, ‐2, and ‐4) in prostate cancer , 2007, The Prostate.
[30] A. Sica,et al. Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.
[31] D. V. Von Hoff,et al. Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.
[32] G. Scagliotti,et al. Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer. , 2006, Clinical lung cancer.
[33] M. Hollenberg,et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. , 2005, Human pathology.
[34] R. Johns,et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. , 2005, The American journal of pathology.
[35] A. Agarwal,et al. PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.
[36] Z. Salah,et al. Differential expression of Protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples , 2005, International journal of cancer.
[37] T. Sawada,et al. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. , 2004, International journal of oncology.
[38] M. Laburthe,et al. Protease-activated Receptor 2 in Colon Cancer , 2004, Journal of Biological Chemistry.
[39] G. Caliendo,et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation , 2004, Hepatology.
[40] G. Neufeld,et al. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] M. Ogawa,et al. Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. , 2003, International journal of oncology.
[42] S. Coughlin,et al. A Role for Thrombin Receptor Signaling in Endothelial Cells During Embryonic Development , 2001, Science.
[43] M. D'Andrea,et al. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. , 2001, The American journal of pathology.
[44] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[45] M. Nakagawa,et al. Prognostic value of tumor‐associated macrophage count in human bladder cancer , 2000, International journal of urology : official journal of the Japanese Urological Association.
[46] T. Billiar,et al. Nitric Oxide Inhibits Apoptosis by Preventing Increases in Caspase-3-like Activity via Two Distinct Mechanisms* , 1997, The Journal of Biological Chemistry.
[47] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] S. Coughlin,et al. The Cloned Thrombin Receptor Is Necessary and Sufficient for Activation of Mitogen-activated Protein Kinase and Mitogenesis in Mouse Lung Fibroblasts , 1996, The Journal of Biological Chemistry.
[49] V. Wheaton,et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.
[50] E. Diamandis,et al. Pancreatic cancer. , 2013, Clinical chemistry.
[51] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[52] P. Reitsma,et al. Cardiovascular , Pulmonary and Renal Pathology Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation , 2010 .
[53] P. Bioulac-Sage,et al. Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis. , 2008, American journal of physiology. Gastrointestinal and liver physiology.